- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Beleave Inc. (“Beleave” or the “Company”) (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has received notification from Health Canada that, upon the Company’s confirmation that the Company’s production, testing, manufacturing, packaging, storing, labelling, shipping and record-keeping of product intended for sale is in compliance with the requirements of the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), Health Canada will arrange a pre-sale inspection. The issuance of a sales license under the ACMPR is in part dependent upon the completion of a satisfactory pre-sale inspection by Health Canada.
Beleave Inc. (“Beleave” or the “Company“) (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has received notification from Health Canada that, upon the Company’s confirmation that the Company’s production, testing, manufacturing, packaging, storing, labelling, shipping and record-keeping of product intended for sale is in compliance with the requirements of the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“), Health Canada will arrange a pre-sale inspection. The issuance of a sales license under the ACMPR is in part dependent upon the completion of a satisfactory pre-sale inspection by Health Canada.
About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.
For further information please contact: Sebastian de Kloet Phone: (905) 979 – 5173 Email: sebastian@beleave.com beleave.com |
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company’s ability to satisfy the conditions associated with its cultivation license, the Company’s ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.
Click here to connect with Beleave Inc. (CNSX:BE) for an Investor Presentation.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.